A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. (HuLuc63-1702)
This study is currently recruiting participants.
Study NCT00726869
Information provided by Facet Biotech
First Received: July 29, 2008
Last Updated: October 14, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
